Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Open this folder and view contents7. The editorial process
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Close this folder13. Partnership and collaboration
View the document13.1 The importance of supportive partners
View the document13.2 Possibilities at national, regional and international levels
Open this folder and view contents13.3 Various forms of collaboration
View the document13.4 Identifying partners and networks
View the document13.5 Clearly define conditions for partnership
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information

13.1 The importance of supportive partners

Many drug bulletins face difficult circumstances, especially when they are first starting, or when resources are limited, as in many developing countries. It may be difficult to obtain needed information, professional advice, financing and the means to assure the drug bulletin’s independence. Collaboration and supportive partnerships are crucial for a new drug bulletin, and can play a key role in the future success of the organization. Every drug bulletin, regardless of the level of its development and experience, can gain strength through the support of other similar publications. This was one of the main motives for creating an international network of drug bulletins, ISDB.

An unpredictable aspect of publishing a bulletin that cannot be ignored is the possibility of legal problems arising from the publication of critical articles and reviews. The existence of reliable partners at national, regional or international levels not only lends support to a bulletin but also enables it to act more independently. Several drug bulletins, such as CITO in Latvia and Geneesmiddelenbulletin in the Netherlands, have faced situations where the support of other organizations enabled them to counter opposition successfully and to continue publishing their bulletin.

As in personal relationships, a prerequisite for successful partnerships and collaboration is that the different parties know each other well enough to establish a relationship that satisfies the needs of the weaker partner without making undue demands on the partners who are providing support.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017